Harvard Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBIO research report →
Range $6 – $6
Price Chart
About the company
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
- CEO
- John D. Duke
- IPO
- 2000
- Employees
- 328
- HQ
- Holliston, MA, US
Get TickerSpark's AI analysis on HBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.60M
- P/E
- -3.29
- Fwd P/E
- 20.14
- PEG
- -0.08
- P/S
- 0.44
- P/B
- 7.74
- EV/EBITDA
- -20.69
- Div Yield
- 0.00%
- Gross Margin
- 57.43%
- Op Margin
- -0.36%
- Net Margin
- -13.20%
- ROE
- -130.06%
- ROIC
- -0.61%
Latest fiscal year · YoY change
- Revenue
- $86.55M-8.1%
- Gross Profit
- $45.88M-16.2%
- Op Income
- $-629,000
- Net Income
- $-56,700,000-357.1%
- EPS
- $-12.80-357.1%
- OCF Growth
- +367.3%
- FCF Growth
- +408.0%
- 52W High
- $10.20
- 52W Low
- $4.00
- 50D MA
- $8.41
- 200D MA
- $6.67
- Beta
- 1.47
- RSI (14)
- 49
- Avg Volume
- 21.63K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Harvard Bioscience posted another quarter of solid revenue growth, but lower-margin mix from legacy products and China led management to cut full-year EBITDA growth guidance while keeping sales and margin targets intact.· November 10, 2026
- Q3 revenue rose 8% year over year to $22.2 million, marking the second straight quarter of strong growth.
- Adjusted gross margin was 57.1% and adjusted EBITDA was $1.8 million, both pressured by a higher mix of lower-margin legacy products, China, and distribution sales.
- Full-year 2026 revenue growth guidance remains 3% to 5%, and adjusted gross margin guidance stays at 57% to 59%.
- Management lowered full-year adjusted EBITDA growth guidance to negative 1% to 4% from 6% to 10%.
- Project Viking remains on track for completion in Q1 2027 and is still expected to generate $3 million in savings in 2027 and $4 million annually thereafter.
Revenue in Q3 2026 was $22.2 million, up 8% year over year. Adjusted gross margin was 57.1%, compared with a lower gross margin profile driven by legacy products, distribution sales, and China. Adjusted EBITDA was $1.8 million, and adjusted EBITDA margin was 7.9%, down from $2.0 million and 9.6% in Q3 2025. GAAP diluted EPS was negative $0.58 versus negative $0.28 last year; adjusted EPS was negative $0.06 versus negative $0.04. For Q4, management guided to revenue of $23.7 million to $25.5 million, adjusted gross margin of 59% to 61%, and adjusted EBITDA of $3.8 million to $4.2 million. For full year 2026, revenue growth guidance remains 3% to 5%, gross margin target remains 57% to 59%, and adjusted EBITDA growth guidance was reduced to negative 1% to 4% from 6% to 10%.
John Duke framed the quarter as another solid step for the business, emphasizing broad-based demand across preclinical platforms, organoids, fluidics, telemetry, and China. He repeatedly pointed to commercial execution and industry tailwinds, including CRO demand, expanding preclinical pipelines, and a growing need for external research partners. His tone was confident but measured, with the main strategic message centered on the company’s innovation pipeline, channel expansion, and the long-term benefits of Project Viking.
Mark Frost focused on the mechanics behind the quarter’s performance: revenue of $22.2 million, adjusted gross margin of 57.1%, adjusted EBITDA of $1.8 million, and adjusted EPS of negative $0.06. He said the margin mix was weighed down by lower-margin legacy products, higher distribution sales, and strength in China, while OpEx rose $0.8 million as salaries, merit, and bonus potential were restored to normalized levels. He also noted cash used in operations of $0.6 million through nine months, cash and cash equivalents of $4.9 million, and net debt of $35.1 million, and said Project Viking should improve cash generation once transition costs roll off in 2027.
Analysts pressed on BTX electroporation, China, academia, and Project Viking. Management said BTX electroporation was up strong double digits year to date, largely from hardware and consumables, and said a GMP/bioproduction launch is expected by midyear next year. On Project Viking, management said 5 of 8 product lines have been moved, fluidics is in parallel build, and the transition should finish over the next five months, with savings of about $1 million per quarter starting in Q2 2027. They also said academic demand remains weak in the U.S. and Europe, but the company is not assuming any NIH-related upside in guidance.
The call showed that core demand is still healthy, with growth across CROs, pharma, biotech, organoids, telemetry, fluidics, and China. Management also said the revenue growth appears to be run-rate rather than one-time shipments, and that Project Viking plus new product localization should lift margins and cash generation in 2027.
The biggest near-term concern is that growth is coming with a less favorable mix, which already forced management to cut full-year EBITDA growth guidance. Academic markets remain weak, especially in Europe, and management said China and distribution sales carry lower margins, while Project Viking still requires execution before the expected savings arrive in 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.8%
- Shares Outstanding
- 4.57M
- Float Shares
- 3.69M
of shares held by institutions
34 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.92M | ▲ 71.43K |
| Two Sigma Advisers, LP | 878.56K | ▲ 635.40K |
| Acadian Asset Management LLC | 179.61K | 0 |
| Vanguard Capital Management LLC | 172.06K | ▲ 2.44K |
| Mink Brook Asset Management LLC | 124.20K | ▲ 90.83K |
| Corsair Capital Management, L.P. | 122.81K | 0 |
| Renaissance Technologies LLC | 94.33K | ▼ 5.00K |
| Two Sigma Investments, LP | 85.53K | ▼ 29.01K |
| Blackrock, Inc. | 61.89K | ▲ 59 |
| Geode Capital Management, LLC | 46.75K | ▼ 802 |
| Vanguard Fiduciary Trust Co | 27.73K | 0 |
| Millennium Management LLC | 27.06K | ▼ 5.56K |
Held by 33 ETFs
Biggest fund positions in HBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | Eade Katherine A. | other | 16,556 |
| Jun 9, 26 | Snider William | other | 16,556 |
| Jun 9, 26 | DENELSKY STEPHEN J | other | 16,556 |
| Jun 9, 26 | Gagnon Robert E. | other | 16,556 |
| Jun 9, 26 | Benson Seth Benjamin | other | 16,556 |
| Mar 20, 26 | Frost Mark T | other | 30,000 |
| Mar 16, 26 | Frost Mark T | buy | 5,000 |
| Mar 20, 26 | Duke John D | other | 75,000 |
| Mar 17, 26 | DENELSKY STEPHEN J | buy | 10,000 |
| Mar 17, 26 | Snider William | buy | 8,475 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HBIO coverage
Recent articles, reports, and earnings notes.
No research on HBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HBIO report →Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Harvard Bioscience Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
globenewswire.com · Nov 4
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
globenewswire.com · Oct 27
Harvard Bioscience Announces Creation of Scientific Advisory Board
globenewswire.com · Oct 6
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 11
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
globenewswire.com · Jul 28
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
globenewswire.com · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.